Clinical Trials in Cincinnati, OH

Browse 244 Cincinnati Medical Studies Across 1147 Cities
115 Phase 3 Trial · 11481 Cincinnati Clinics

Display Results

All

Most EffectiveMost SafeSenior FriendlyPediatricNo Placebo

Clinical Trials Clinical Trials in Cincinnati, OH

Reviewed by Michael Gill, B. Sc.

Image of Cincinnatti Childrens Hospital in Cincinnati, United States.

Phase-Based Progress Estimates

Age Group 1: Patients Aged 3 To 23 Monthsfor Central Nervous System Diseases

This Phase II open-label, uncontrolled, multicenter trial is designed to investigate the pharmacokinetic (PK) profile of gadopiclenol in plasma, in pediatric patients aged up to 23 months inclusive (term neonates or preterm infants after the neonatal period), using a population PK approach. Primary objective is to evaluate the PK profile of gadopiclenol in plasma following single intravenous injection of 0.05 mmol/kg body weight (BW) in pediatric population aged up to 23 months (inclusive) scheduled for a contrast-enhanced MRI examination of any body region including central nervous system (CNS).

Cincinnatti Childrens Hospital (+1 Sites)Donna R Roberts, MDGuerbet

Image of Medical Facility in Cullman, United States.

Phase-Based Progress Estimates

Sulopenem Etzadroxil/probenecidfor Urinary Tract Infections

IT001-310 is a clinical study which compares the effectiveness of oral sulopenem versus oral amoxicillin/clavulanate for the treatment of adult women with uncomplicated urinary tract infection.

Medical Facility (+49 Sites)Sailaja Puttagunta, MDIterum Therapeutics, International Limited

Image of North Alabama Research Center, LLC in Athens, United States.

Phase-Based Progress Estimates

MRNA-1010for Hay fever

This trial will test if a new vaccine can prevent seasonal influenza in adults aged 50 and over.

North Alabama Research Center, LLC (+99 Sites)ModernaTX, Inc.

Image of Research Site in Nashville, United States.

Phase-Based Progress Estimates

Cohort Bfor Breast Cancer

This study to learn more about olaparib and olaparib plus durvalumab combination therapy and also to better understand the studied disease, breast cancer, and associated health problems. Olaparib is a type of drug called a PARP (poly [adenosine diphosphate-ribose] polymerase) inhibitor. PARP inhibitors can destroy cancer cells that are not good at repairing DNA damage. Olaparib is also approved by US Food and Drug Administration (FDA), European Medicines Agency (EMA) and in other countries for treating women with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. Durvalumab is a type of anticancer drug called immunotherapy that targets cancer cells by blocking the signal that prevents the immune system from seeing the cancer cell. Your immune system can then attack and kill the cancer cells. Durvalumab is approved by the FDA and the EMA for the treatment of patients with locally advanced non-small cell lung cancer after receiving chemoradiation therapy and extensive-stage small cell lung cancer in combination with chemotherapy. Some parts of this study are experimental, which means that durvalumab and the combination of olaparib and durvalumab are still in the development stage for the treatment of breast cancer, and they are not approved for treatment of breast cancer, except for use in research studies like this.

Research Site (+9 Sites)Anitra Fielding, MBChBAstraZeneca

Image of City of Hope Medical Center in Duarte, United States.

Phase-Based Progress Estimates

CF33-hNISfor Cancer

This trial is testing a new cancer treatment that can be given either intravenously or directly into tumors. The safety of the treatment will be evaluated in patients with advanced solid tumors.

City of Hope Medical Center (+4 Sites)Imugene Limited

Image of Novo Nordisk Investigational Site in Atlanta, United States.

Phase-Based Progress Estimates

Somapacitanfor Noonan Syndrome

This trial is testing a new growth hormone against a current one to see if it's more effective in children with Turner Syndrome, Noonan Syndrome, Idiopathic Short Stature, or who were born small and stay small.

Novo Nordisk Investigational Site (+34 Sites)Clinical Transparency dept. 2834Novo Nordisk A/S

Image of Sage Investigational Site in Hialeah, United States.

Phase-Based Progress Estimates

SAGE-718for Cognitive Decline

This trial will test if SAGE-718 can improve cognitive performance in people with Parkinson's disease and mild cognitive impairment.

Sage Investigational Site (+6 Sites)Sage Therapeutics

Image of Rehabilitation & Neurological Services /ID# 240054 in Huntsville, United States.

Phase-Based Progress Estimates

Ubrogepantfor Migraine

FDA Approved Drug

This trial is investigating the long-term safety and tolerability of ubrogepant in children and adolescents with a history of migraine.

FDA Approved Drug

Rehabilitation & Neurological Services /ID# 240054 (+99 Sites)ALLERGAN INC.AbbVie

Image of Clinical Study Site in Encino, United States.

Phase-Based Progress Estimates

Danicopanfor Geographic Atrophy

This trial is testing a new drug for age-related macular degeneration. There are 4 groups of patients, each taking different doses of the drug or a placebo. The trial will last 104 weeks, with follow up 30 days after the last dose.

Clinical Study Site (+40 Sites)Alexion Pharmaceuticals

Image of Fomatmedicalresearch in Camarillo, United States.

Phase-Based Progress Estimates

IVA337for Fatty Liver

This trial is testing a new drug, lanifibranor, to see if it can treat adults with a fatty liver disease called NASH, and who also have liver fibrosis stage 2 or 3.

Fomatmedicalresearch (+66 Sites)Sven Francque, MDInventiva Pharma

Image of Cincinanti Childrens Hospital Medical Center in Cincinnati, United States.

Phase-Based Progress Estimates

ANMT Biofeedbackfor Anterior Cruciate Ligament Tear

This trial will study how well a new type of training that uses brain feedback helps people's muscles get stronger.

Cincinanti Childrens Hospital Medical Center (+1 Sites)Gregory D Myer, PhD

Image of Children's Hospital of Alabama in Birmingham, United States.

Phase-Based Progress Estimates

Arm I (HR-FAV B-ALL)for B Acute Lymphoblastic Leukemia

FDA Approved Drug

This trial is studying whether adding inotuzumab ozogamicin to standard chemotherapy for high-risk B-cell acute lymphoblastic leukemia (B-ALL) improves outcomes.

FDA Approved Drug

Children's Hospital of Alabama (+99 Sites)Jennifer L McNeer

Image of HonorHealth Research Institute in Scottsdale, United States.

Phase-Based Progress Estimates

Gilteritinibfor Leukemia, Myelocytic, Acute

Waitlist Available

FDA Approved Drug

This trial will compare the effectiveness of two drugs, gilteritinib and midostaurin, in patients with FLT3 acute myeloid leukemia who are also receiving standard chemotherapy.

Waitlist Available

FDA Approved Drug

HonorHealth Research Institute (+43 Sites)Selena Luger, MDAstellas Pharma Inc

Image of Anchorage Associates in Radiation Medicine in Anchorage, United States.

Phase-Based Progress Estimates

Pembrolizumabfor Stage IIIB Lung Cancer AJCC v8

FDA Approved Drug

This trial is studying whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or without pembrolizumab works better in treating patients with advanced non-squamous non-small cell lung cancer.

FDA Approved Drug

Anchorage Associates in Radiation Medicine (+99 Sites)Hossein Borghaei

Image of Sean N Parker Center for Allergy and Asthma Research, Department of Medicine, Division of Pulmonary & Critical Care Medicine Stanford University School of Medicine in Mountain View, United States.

Phase-Based Progress Estimates

Tri-lipid Skin Barrier Cream (Epiceram)for Infantile Eczema

FDA Approved Drug

This trial is designed to compare the effectiveness of proactive and reactive treatment methods for atopic dermatitis (AD) in infants. The proactive treatment includes the use of a skin barrier cream or moisturizer and the proactive use of fluticasone propionate cream. The reactive treatment for AD is currently the standard of care and does not include the proactive use of these two products. The aim is to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).

FDA Approved Drug

Sean N Parker Center for Allergy and Asthma Research, Department of Medicine, Division of Pulmonary & Critical Care Medicine Stanford University School of Medicine (+4 Sites)Sayantani Sindher, MD

Image of Cancer Center at Saint Joseph's in Phoenix, United States.

Phase-Based Progress Estimates

Radical Cystectomyfor Carcinoma

FDA Approved Drug

This trial studies gemcitabine hydrochloride and cisplatin as a treatment for bladder cancer.

FDA Approved Drug

Cancer Center at Saint Joseph's (+99 Sites)Gopa Iyer, MD

Image of Fairbanks Memorial Hospital in Fairbanks, United States.

Phase-Based Progress Estimates

Antiandrogen Therapyfor Castration Levels of Testosterone

FDA Approved Drug

This trial is testing abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, to see how well it works in treating patients with castration-resistant prostate cancer that has spread to other parts of the body and has been previously treated with docetaxel.

FDA Approved Drug

Fairbanks Memorial Hospital (+99 Sites)Christos Kyriakopoulos

Image of Anchorage Associates in Radiation Medicine in Anchorage, United States.

Phase-Based Progress Estimates

Tazemetostatfor Malignant Neoplasms

Waitlist Available

FDA Approved Drug

This trial looks at how well tazemetostat works in treating patients with ovarian or endometrial cancer that has come back.

Waitlist Available

FDA Approved Drug

Anchorage Associates in Radiation Medicine (+99 Sites)Ramez N Eskander

Image of Yale University School of Medicine - Infectious Diseases in New Haven, United States.

Phase-Based Progress Estimates

Pritelivirfor Herpes Simplex

FDA Approved Drug

This trial is testing two different drugs to see which is more effective and has fewer side effects in people with HSV infections that are resistant or susceptible to acyclovir.

FDA Approved Drug

Yale University School of Medicine - Infectious Diseases (+24 Sites)AiCuris Anti-infective Cures GmbH

Image of Children's Hospital of Alabama in Birmingham, United States.

Phase-Based Progress Estimates

Cisplatinfor Extragonadal Embryonal Carcinoma

FDA Approved Drug

This trial is testing how well active surveillance, bleomycin, etoposide, carboplatin or cisplatin work in treating pediatric and adult patients with germ cell tumors.

FDA Approved Drug

Children's Hospital of Alabama (+99 Sites)A. L Frazier

Image of Weill Cornell Medical College in New York, United States.

Phase-Based Progress Estimates

KPT-8602for Muscular Dystrophy

FDA Approved Drug

This trial will assess the safety, tolerability, and preliminary efficacy of KPT-8602, an oral XPO1 inhibitor, in patients with relapsed/refractory multiple myeloma, metastatic colorectal cancer, metastatic castration resistant prostate cancer, higher risk myelodysplastic syndrome, acute myeloid leukemia, and newly diagnosed intermediate/high-risk MDS.

FDA Approved Drug

Weill Cornell Medical College (+24 Sites)Jatin Shah, MDKaryopharm Therapeutics Inc

Image of Nanticoke Memorial Hospital in Seaford, United States.

Phase-Based Progress Estimates

Capecitabinefor Intestines

FDA Approved Drug

This trial is studying temozolomide and capecitabine to see how well they work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas.

FDA Approved Drug

Nanticoke Memorial Hospital (+23 Sites)Jennifer Eads

Image of Anchorage Associates in Radiation Medicine in Anchorage, United States.

Phase-Based Progress Estimates

FAK Inhibitor GSK2256098for Intracranial Meningioma

FDA Approved Drug

This trial is studying how well vismodegib, FAK inhibitor GSK2256098, and capivasertib work in treating patients with progressive meningioma.

FDA Approved Drug

Anchorage Associates in Radiation Medicine (+99 Sites)Priscilla Brastianos, MDGenentech, Inc.

Image of University of Alabama at Birmingham Cancer Center in Birmingham, United States.

Phase-Based Progress Estimates

Subprotocol R (BRAF Fusion Or BRAF Non-V600 Mutation)for Lymphoma

FDA Approved Drug

This trial uses genomic testing to direct cancer treatment. Patients with cancer that has progressed after standard treatment or for which there is no agreed-upon treatment may benefit.

FDA Approved Drug

University of Alabama at Birmingham Cancer Center (+99 Sites)Keith T Flaherty

Image of Research Site in Aurora, United States.

Phase-Based Progress Estimates

Carfilzomibfor Leukemia, Lymphoid

FDA Approved Drug

This trial is for children with relapsed or refractory acute lymphoblastic leukemia. The goal is to see if carfilzomib is safe and effective when combined with other drugs.

FDA Approved Drug

Research Site (+30 Sites)MDAmgen

25 Cincinnati Clinical Trials Near Me

Top Cities for Cincinnati Clinical Trials

Image of Cincinnati in Ohio.

Cincinnati

217Active Trials

Cincinnati Children's Hospital Medical CenterTop Active Site

Image of Los Angeles in California.

Los Angeles

204Active Trials

Cedars Sinai Medical CenterTop Active Site